Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital, and preliminary PET imaging data are showing encouraging signals in acute MS lesions. This milestone is significant because the novel imaging technique aims to differentiate between demyelinated nerve fibers that may still be viable and those that have undergone permanent damage, offering a more precise method to measure myelin loss and repair.
The implications of this progress extend beyond the imaging study itself. These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool paired with a drug candidate that addresses the underlying cause of MS creates a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions, a critical validation for both the diagnostic and therapeutic approaches.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates in various stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
The company also invented unbuzzd, a product aimed at reducing alcohol intoxication, and spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains ownership of 19.84% of UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
Investors and stakeholders can stay updated on the latest news and developments from Quantum BioPharma through the company’s newsroom at https://nnw.fm/QNTM. The full article discussing these developments can be accessed at https://nnw.fm/fsDHa.
